Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A new examination of Sustiva- and Viramune-based triple-drug regimens has shown that it isn't the choice between the two nonnucleoside analogs that predicts long-term viral control among treatment-naive HIVers but rather the accompanying nucleosides. The review, published in the April 6 issue of the Journal of Acquired Immune Deficiency Syndromes, shows that both Sustiva and Viramune are most successful when paired with two newer nukes than with such older combinations as Zerit plus Epivir or Videx plus Viread.
DON'T MISS THE OUT100 SPECIAL 3 DAY MARATHON STARTING NOVEMBER 24TH!
Journey through the year’s influential Out100 – the most iconic and long-standing celebration of LGBTQ+ icons and allies – in a 1-hour television special spotlighting the LGBTQ+ people shaping the world today.
WATCH & LIVESTREAM ON ADVOCATECHANNEL.COM
AND ON THE ADVOCATE CHANNEL APP
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Plus: Featured Video
Latest Stories
7 Uplifting Films To Celebrate Trans Awareness Week & Where To Stream Them
November 17 2023 10:25 AM
Out's Deal Guide: Grab Your 50% Off Amazon Fire Tablets & More Recommended Deals on Amazon Today!
November 03 2023 3:44 PM
Unlock Massive Savings at 'The Holiday Shop': Amazon's Hottest Deals of the Season Await!
November 02 2023 2:17 PM
Dianne Feinstein’s Commitment to People Living With HIV Won’t Be Forgotten
November 02 2023 1:27 PM
PEPFAR in Peril: The Far-Right Wants to End the Lifesaving Global HIV Program
October 24 2023 1:52 PM
Plus Nov/Dec Issue: PEPFAR in Danger & Our Allies and Advocates of the Year
October 23 2023 11:53 AM
Trending stories
Most Recent
Recommended Stories for You
HIV Plus Editors
Editor
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.